These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1315 related items for PubMed ID: 17624200

  • 21. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
    Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH, PROACTIVE Study Group.
    Hepatology; 2004 Dec; 40(6):1450-8. PubMed ID: 15565613
    [Abstract] [Full Text] [Related]

  • 22. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
    Glaspy JA, Charu V, Luo D, Moyo V, Kamin M, Wilhelm FE.
    Cancer; 2009 Mar 01; 115(5):1121-31. PubMed ID: 19170225
    [Abstract] [Full Text] [Related]

  • 23. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
    Biesma B, van de Werf PR, Melissant CF, Brok RG.
    Lung Cancer; 2007 Oct 01; 58(1):104-11. PubMed ID: 17601632
    [Abstract] [Full Text] [Related]

  • 24. Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery.
    Stovall TG.
    J Reprod Med; 2001 May 01; 46(5 Suppl):531-8. PubMed ID: 11396387
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.
    Crit Care Med; 2006 Jun 01; 34(6):1661-7. PubMed ID: 16607233
    [Abstract] [Full Text] [Related]

  • 26. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.
    J Clin Oncol; 2005 Sep 01; 23(25):5960-72. PubMed ID: 16087945
    [Abstract] [Full Text] [Related]

  • 27. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
    Agnihotri P, Telfer M, Butt Z, Jella A, Cella D, Kozma CM, Ahuja M, Riaz S, Akamah J.
    J Am Geriatr Soc; 2007 Oct 01; 55(10):1557-65. PubMed ID: 17697104
    [Abstract] [Full Text] [Related]

  • 28. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.
    Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL.
    J Clin Oncol; 2006 Mar 01; 24(7):1079-89. PubMed ID: 16505427
    [Abstract] [Full Text] [Related]

  • 29. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS.
    Am J Gastroenterol; 2003 Nov 01; 98(11):2491-9. PubMed ID: 14638354
    [Abstract] [Full Text] [Related]

  • 30. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
    Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C.
    J Clin Oncol; 2009 Dec 01; 27(34):5751-6. PubMed ID: 19884550
    [Abstract] [Full Text] [Related]

  • 31. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
    Quirt I, Kovacs M, Couture F, Turner AR, Noble M, Burkes R, Dolan S, Plante RK, Lau CY, Chang J.
    Oncologist; 2006 Jan 01; 11(1):73-82. PubMed ID: 16401716
    [Abstract] [Full Text] [Related]

  • 32. Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapy.
    Spaëth D, Desablens B, Rodon P, Mennecier B, Oudard S, Moullet I, Ghomari K, Bergougnoux L, Bleuzen P, Jenabian A, Ifrah N.
    Oncology; 2008 Jan 01; 74(1-2):112-8. PubMed ID: 18547966
    [Abstract] [Full Text] [Related]

  • 33. Weekly epoetin alfa treatment of anemia in patients with cancer not undergoing therapy.
    Shasha D, Williams D.
    J Support Oncol; 2006 Mar 01; 4(3):129-35. PubMed ID: 16553139
    [Abstract] [Full Text] [Related]

  • 34. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA, Vogel CL, Gralow JR, Williams D, Procrit Study Group.
    Clin Breast Cancer; 2005 Jun 01; 6(2):132-42. PubMed ID: 16001991
    [Abstract] [Full Text] [Related]

  • 35. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU.
    J Clin Oncol; 2008 Feb 01; 26(4):592-8. PubMed ID: 18235117
    [Abstract] [Full Text] [Related]

  • 36. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN.
    J Clin Oncol; 2007 Mar 20; 25(9):1027-32. PubMed ID: 17312332
    [Abstract] [Full Text] [Related]

  • 37. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A, Epoetin Zeta Study Group.
    Adv Ther; 2010 Feb 20; 27(2):105-17. PubMed ID: 20369312
    [Abstract] [Full Text] [Related]

  • 38. Treatment of cancer-related anemia with epoetin alfa: a review.
    Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M, De Dosso S, Buzzoni R, Bajetta E.
    Cancer Treat Rev; 2004 Oct 20; 30(6):563-75. PubMed ID: 15325036
    [Abstract] [Full Text] [Related]

  • 39. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
    Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC.
    Curr Med Res Opin; 2006 Jul 20; 22(7):1403-13. PubMed ID: 16834839
    [Abstract] [Full Text] [Related]

  • 40. [Improvement of anemia and quality of life of patients with prostate cancer by treatment with human recombinant erythropoietin].
    Queipo Zaragozá JA, Chicote Pérez F, Beltrán Meseguer JF, Borrell Palanca A, Giner Marco V, Esteve Claramunt J, Pastor Sempere F.
    Arch Esp Urol; 2004 Jul 20; 57(1):35-40. PubMed ID: 15112869
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 66.